Evidence map›Paper›PMID 41575185›Full record

ArticleeLife2026

HIV-specific CD8+ T-cell proliferative response 24 weeks after early antiretroviral therapy initiation is associated with the subsequent reduction in the viral reservoir.

Pien Margien van Paassen, Alexander O Pasternak, Dita C Bolluyt, Karel A van Dort, Ad C van Nuenen, Irma Maurer, Brigitte Boeser-Nunnink, Ninée V E J Buchholtz, Tokameh Mahmoudi, Cynthia Lungu and 10 more

Abstract read
In one paragraph

Article in eLife, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Pien Margien van Paassen *Department of Experimental Immunology, Amsterdam UMC, Amsterdam, Netherlands.ORCID https://orcid.org/0000-0002-7300-3232
Alexander O Pasternak *Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, Netherlands.ORCID https://orcid.org/0000-0002-4097-4251
Dita C BolluytAmsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, Netherlands.
Karel A van DortDepartment of Experimental Immunology, Amsterdam UMC, Amsterdam, Netherlands.
Ad C van NuenenDepartment of Experimental Immunology, Amsterdam UMC, Amsterdam, Netherlands.
Irma MaurerDepartment of Experimental Immunology, Amsterdam UMC, Amsterdam, Netherlands.
Brigitte Boeser-NunninkDepartment of Experimental Immunology, Amsterdam UMC, Amsterdam, Netherlands.
Ninée V E J BuchholtzDepartment of Medical Microbiology, Translational Virology, University Medical Center Utrecht, Utrecht, Netherlands.
Tokameh MahmoudiDepartment of Biochemistry and Department of Pathology, Erasmus Medical Center, Rotterdam, Netherlands.ORCID https://orcid.org/0000-0002-2060-9353
Cynthia LunguDepartment of Biochemistry and Department of Pathology, Erasmus Medical Center, Rotterdam, Netherlands.
Reinout van CrevelDepartment of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands.
Casper RokxDepartment of Internal Medicine and Department of Medical Microbiology and InfectiousDiseases, Erasmus University Medical Center, Rotterdam, Netherlands.
Jori SymonsDepartment of Medical Microbiology, Translational Virology, University Medical Center Utrecht, Utrecht, Netherlands.
Monique NijhuisDepartment of Medical Microbiology, Translational Virology, University Medical Center Utrecht, Utrecht, Netherlands.
Annelou L I P van der VeenDepartment of Internal Medicine, section Infectious Diseases, Amsterdam UMC, location AMC, Amsterdam, Netherlands.
Liffert VogtApheresis Unit,Dianet, location Amsterdam UMC, Amsterdam, Netherlands.
Michelle J KlouwensDepartment of Internal Medicine, section Infectious Diseases, Amsterdam UMC, location AMC, Amsterdam, Netherlands.
Jan M PrinsDepartment of Internal Medicine, section Infectious Diseases, Amsterdam UMC, location AMC, Amsterdam, Netherlands.
Neeltje A Kootstra *Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, Netherlands.ORCID https://orcid.org/0000-0001-9429-7754
Godelieve J de Bree *Department of Internal Medicine, section Infectious Diseases, Amsterdam UMC, location AMC, Amsterdam, Netherlands.ORCID https://orcid.org/0000-0002-5852-5833

Funding

Aids Fonds P-60803amfAR, The Foundation for AIDS Research 1110680-77-RPRLGilead Sciences CO-NL-985-6195Nederlandse Organisatie voor Wetenschappelijk Onderzoek KICH2.V4P.AF23.001
6 · The paper itself

Abstract

Antiretroviral therapy (ART) initiated in the acute phase of HIV infection (AHI) results in a smaller viral reservoir. However, the impact of early HIV-specific T-cell responses on long-term reservoir dynamics is less well characterized. Therefore, we measured the size of the viral reservoir and functionality of HIV-specific CD8+ T-cell responses after the acute phase at 24 and 156 weeks after ART initiation in people with HIV who started treatment during AHI. A significant reduction in total and defective HIV DNA and a trend toward a reduction in intact HIV DNA were observed between 24 and 156 weeks. Functional CD8+ T-cell responses against HIV peptides Env, Gag, Nef, and Pol were maintained over 3 years after treatment initiation. The proliferative capacity of HIV-specific CD8+ T-cells at 24 weeks of ART was predictive of the degree of reduction in total and defective HIV DNA between 24 and 156 weeks, suggesting HIV-specific CD8+ T-cells may at least partially drive the decline of the viral reservoir. Therefore, enforcing HIV-specific immune responses as early as possible after diagnosis of AHI should be a central focus of HIV cure strategies.

Indexed as

Anti-Retroviral AgentsCD8-Positive T-LymphocytesCell ProliferationHIV-1HIV InfectionsDNA, ViralHumansViral LoadAnti-Retroviral AgentsDNA, Viralantiretroviral therapyantiviral drugsantiviral immunityHIVHIV reservoirhumanimmunologyinfectious diseaseinflammationmicrobiologyviruses

Identifiers

PMID41575185
PMCPMC12829989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.